COV ENT 1
Alternative Names: COV-ENT-1Latest Information Update: 28 May 2024
At a glance
- Originator Enterin
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Inhalation)
- 17 Apr 2020 Preclinical trials in COVID-2019 infections in USA (Inhalation)
- 17 Apr 2020 Enterin receives positive feedback from the US FDA to laying out the path for a phase I/II trial for COVID-2019 infections in USA